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Anti-inﬂammatory dopamine- and serotonin-based
endocannabinoid epoxides reciprocally regulate
cannabinoid receptors and the TRPV1 channel
1234567890():,;

William R. Arnold1,6, Lauren N. Carnevale
Hongzhen Hu 2 & Aditi Das4,5 ✉

1,6,

Zili Xie2, Javier L. Baylon3, Emad Tajkhorshid

3,

The endocannabinoid system is a promising target to mitigate pain as the endocannabinoids
are endogenous ligands of the pain-mediating receptors—cannabinoid receptors 1 and 2 (CB1
and CB2) and TRPV1. Herein, we report on a class of lipids formed by the epoxidation of Narachidonoyl-dopamine (NADA) and N-arachidonoyl-serotonin (NA5HT) by epoxygenases.
EpoNADA and epoNA5HT are dual-functional rheostat modulators of the endocannabinoidTRPV1 axis. EpoNADA and epoNA5HT are stronger modulators of TRPV1 than either NADA
or NA5HT, and epoNA5HT displays a signiﬁcantly stronger inhibition on TRPV1-mediated
responses in primary afferent neurons. Moreover, epoNA5HT is a full CB1 agonist. These
epoxides reduce the pro-inﬂammatory biomarkers IL-6, IL-1β, TNF-α and nitrous oxide and
raise anti-inﬂammatory IL-10 cytokine in activated microglial cells. The epoxides are spontaneously generated by activated microglia cells and their formation is potentiated in the
presence of anandamide. Detailed kinetics and molecular dynamics simulation studies provide evidence for this potentiation using the epoxygenase human CYP2J2. Taken together,
inﬂammation leads to an increase in the metabolism of NADA, NA5HT and other eCBs by
epoxygenases to form the corresponding epoxides. The epoxide metabolites are bioactive
lipids that are potent, multi-faceted molecules, capable of inﬂuencing the activity of CB1, CB2
and TRPV1 receptors.
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pioids are highly addictive pain medications that are
susceptible for abuse. The age-adjusted death rate by
opioid overdose was determined to be nearly 20 per
100,000 people in the United States in 2016, according to a report
by the Centers for Disease Control and Prevention1. Hence, there
is a need for therapeutic alternatives to opioids that combat
inﬂammation and the associated pain.
Pain is regulated primarily by sensory afferent neurons and
immune cells. Both of these cell types are rich sources of lipid
mediators. Lipid mediators are generated via the enzymatic oxidation of dietary omega-3 and omega-6 polyunsaturated fatty
acids (PUFAs). The pro-inﬂammatory lipid mediators contribute
to pain sensitivity by activating the GPCRs in the sensory neurons
to increase membrane excitability and pain response2. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are used to inhibit
cyclooxygenases, leading to a decrease in the synthesis of proinﬂammatory lipid metabolites such as prostaglandin E2 (PGE2),
thereby decreasing inﬂammatory pain3. On the other hand, antiinﬂammatory and pro-resolving lipid mediators suppress and
resolve the inﬂammatory process, and thus attenuate inﬂammatory pain4,5. Hence, lipid mediators can ﬁne-tune the pain
response and have been at the center for the development of
alternative non-opioid pain therapeutics6.
Additionally, cannabis has been used for centuries to reduce
nociceptive pain either alone or in combination with opioids7.
The primary components of cannabis interact in the body with
cannabinoid receptors 1 and 2 (CB1 and CB2) and other
GPCRs8,9. An endogenous class of bioactive lipids, known as
endocannabinoids (eCBs), activates CB receptors and suppresses
inﬂammation and pain sensitization10. The eCBs are derivatives
of dietary omega-3 and omega-6 PUFAs and are generated by
damaged neurons and inﬂamed tissues. CB1 receptors are highly
expressed in the central nervous system, mostly in the presynaptic
region, and there is substantial CB1 expression in the nociceptive
sensory neurons. It has been shown that under different pain
conditions there is a concomitant increase in CB1 expression11.
Hence, there is sufﬁcient evidence that CB1 mediates the psychotropic effects of cannabinoids such as modulating nociceptive
pain, as well as modulating inﬂammation8,12. CB2 is mostly
expressed in immune cells and mediates the anti-inﬂammatory
effects of cannabinoids, which indirectly contributes to the antinociception of acute inﬂammatory pain12,13. CB2 receptor activation exerts profound anti-nociceptive effects in animal models
of acute, inﬂammatory, and neuropathic pain14.
In addition to CB1 and CB2, a subclass of the eCBs act through
transient receptor potential vanilloid 1 (TRPV1)15. TRPV1 is a
non-selective cation channel that is activated by noxious temperatures, pH, and inﬂammatory agents16,17. TRPV1 often
spearheads nociceptive pain signaling, and thus antagonizing
TRPV1 can reduce pain. Paradoxically, the activation of TRPV1
by small molecules such as capsaicin (CAP), the spicy component
of chili peppers, can also alleviate pain by desensitizing
TRPV1 signaling18. TRPV1 also exhibits pro- and antiinﬂammatory effects19.
Recently, it has been postulated that there is a crosstalk
between CB1 and TRPV1 receptors, which are co-localized in
dorsal root ganglion (DRG) and in neuron-enriched mesencephalic cultures, hippocampus, and cerebellum20. Therefore, the
eCB system and TRPV1 axis provides a promising target to
develop pain and inﬂammation therapeutics. For example,
CMX-020 (Patent US8658632B2) is a novel drug based on the
structure of eCBs and is in development to alleviate pain by
binding to both cannabinoid receptors and TRPV1. Endogenous molecules and their synthetic derivatives may provide
insight into effective therapeutic strategies with which to target
the eCB-TRPV1 axis.
2

The best-studied eCB is anandamide (N-arachidonoyl-ethanolamine: AEA), which is derived from the omega-6 PUFA
arachidonic acid (AA)21. Besides AEA, other eCBs such as Narachidonoyl-dopamine (NADA) and N-arachidonoyl-serotonin
(NA5HT) are also derivatives of AA (Fig. 1). These dopamine22,23
and serotonin24,25 derivatives were identiﬁed in vivo in brain and
intestinal tissues. It was shown that NADA binds with a higher
afﬁnity to CB1 than to CB222; however, conclusive evidence for
NA5HT binding to CB1/2 has yet to emerge. Additionally,
NADA was shown to be an agonist of TRPV126 and NA5HT is
an antagonist of TRPV1, which results in analgesia27. Hence,
NADA and NA5HT are classiﬁed as endovanilloids (eVDs) for
their actions at the TRPV1 (vanilloid) receptor. Interestingly,
NADA has low-afﬁnity binding to DA receptors22, and the stimulation of degranulation in mast cells by NA5HT suggests it
does not activate the 5HT receptors28. Therefore, NADA and
NA5HT do not display typical DA or 5HT responses and are
instead regulators of TRPV1.
To add to the complexity of lipid metabolism, cytochromes
P450 (CYPs) are known to epoxidize lipids into antiinﬂammatory and anti-pain mediators that are more effective
than the parent molecules. For example, CYPs convert AA and
omega-3 PUFAs into epoxy-PUFAs that have been shown to
decrease pain29,30. Recently, the CYP-mediated metabolism of
eCBs was shown to produce epoxy-eCBs that exhibit CB2
receptor selectivity and are anti-inﬂammatory and antitumorigenic31–33. For instance, CYPs epoxidize AEA into epoxyeicosatrienoic acid ethanolamides (EET-EAs) that bind to CB2
receptors31,34,35.
Herein, we evaluated whether epoxides of eVDs are more
effective than parent eVDs at targeting cannabinoid receptors and
TRPV1, and whether they are anti-inﬂammatory. We report a
class of dual-functional epoxides of NADA and NA5HT (epoNADA and epoNA5HT, respectively) that reciprocally regulate
both cannabinoid receptors (CB1 and CB2) and TRPV1 (Fig. 1).
We synthesized NADA, NA5HT, 14′,15′-epoNADA, and 14′,15′epoNA5HT. Using targeted lipidomics, we were able to identify
the eVDs and epoxy-eVDs in porcine brain tissue, but because of
the variability of the results we cannot deﬁnitively conclude their
presence and levels in vivo. We then explored if NADA and
NA5HT are potentially epoxidized under inﬂammatory conditions. We show that epoNADA and epoNA5HT are formed
under inﬂammatory conditions by CYP epoxygenases and show
that AEA potentiates the formation of epoNADA in microglial
cells. We show that one potential mechanism of this potentiation
may be through multiple-ligand binding to CYP-Nanodiscs using
in vitro kinetics methods and molecular dynamics (MD) simulations. We further demonstrate that epoNA5HT is a potent
TRPV1 antagonist suppressing intracellular Ca2+ response and
membrane currents provoked by the TRPV1 ligand CAP in the
primary afferent neurons. Altogether, we show that epoNADA
and epoNA5HT act as dual CB1/2 and TRPV1 ligands and
exhibit anti-inﬂammatory activity. These molecules are potential candidates for the development of pain therapeutics.
Results
Biosynthesis of epoxy-endovanilloids (eVDs). We ﬁrst determined the levels of NADA and NA5HT in porcine brain as they
express similar CYP isozymes to humans. As the epoxidation of
PUFAs and eCBs by CYPs occurs mainly on the terminal
alkene32,34,36, we synthesized 14′,15′-epoNADA and 14′,15′epoNA5HT (Fig. 2a) (Supplementary Figs. 1–5). As shown in
Fig. 2b Method 1, we developed an liquid chromatography with
tandem mass spectrometry (LC-MS/MS) quantitation method in
the selected reaction monitoring (SRM) mode to quantify NADA,
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Fig. 1 The endovanilloid (eVD) pathway and structures of 14’,15’-epoNADA and 14’,15’-epoNA5HT. NADA and NA5HT are synthesized by fatty acid
amid hydrolase and other unidentiﬁed enzymes by the conjugation of arachidonic acid (AA) with dopamine (DA) or serotonin (5HT), respectively. NADA
and NA5HT are known modulators of cannabinoid receptors and TRPV1; however, they do not activate DA or 5HT receptors. Herein, we study the
epoxidation of NADA and NA5HT by CYP epoxygenases and test their effects on cannabinoid receptors and TRPV1.

NA5HT, 14′,15′-epoNADA, 14′,15′-epoNA5HT, and AEA from
brain tissue and microglial cells.
Herein, we measured 1.7 and 1.9 pmol of NADA (0.182 ±
0.081 pmol g−1 wet tissue) and 11.3 and 4.9 pmol of NA5HT
(0.686 ± 0.006 pmol g−1 wet tissue) from the cerebella of two pig
brains, and the values were very low in two more pig brains that
were analyzed. From the hippocampus–thalamus–hypothalamus
regions, we recovered 0.4 and 0.5 pmol of NADA (0.039 ± 0.009
pmol g−1 wet tissue) and 0.2 and 0.1 pmol of NA5HT (0.010 ±
0.003 pmo g−1 wet tissue) in two pig brains. The epoxy-eVDs
levels were variable and often below detection limit due to the low
abundance of their parent molecules. Overall, the levels of NADA
and NA5HT are much less than AEA in rat and pig brains32
(Supplementary Note 1).
In the ﬁeld of lipid metabolites, there is strong evidence that
the production of lipid metabolites is localized to the site of action
and that there is a rapid subsequent degradation37.
This leads to low plasma/tissue levels of most lipid metabolites.
Hence, we studied the epoxidation of these lipid metabolites in
microglial cells. Microglial cells, the innate immune cells of the
brain, are activated during neuroinﬂammation and play important roles in pain modulation38. Previously, it was demonstrated
that CYPs are upregulated during neuroinﬂammation39. Hence,
we used BV2 microglial cells to determine the production of eVD
epoxides from NADA or NA5HT under an inﬂammatory
stimulus. We stimulated microglial cells with lipopolysaccharide

(LPS), followed by the addition of NADA or NA5HT32. We
found that within 30 min of incubation, 14′,15′-epoNADA and
14′,15′-epoNA5HT were formed under LPS stimulation. Interestingly, these molecules are also produced without LPS
stimulation showing that these molecules are made spontaneously
by resting microglial cells (Fig. 2c). Importantly, the production
of these metabolites were partially inhibited in the presence of
SKF 525A (non-speciﬁc CYP epoxygenase inhibitor) demonstrating that the eVD epoxides are produced partly by enzymatic
oxidation by CYP epoxygenases40 (Fig. 2c). However, there are
several other CYPs in the microglial cells that may be producing
these epoxidized metabolites, which can explain the partial
inhibition.
Epoxygenation of eVDs in the presence of AEA. The endogenous levels of AEA are much higher than NADA and NA5HT.
Furthermore, it has been shown that various brain CYPs such as
CYP2J2 and CYP2D6 convert AEA into AEA epoxides (EET-EAs).
Therefore, to understand the substrate speciﬁcity of CYPs when
both substrates (AEA and NADA or NA5HT) are present, we used
the activated microglial cells to study the co-metabolism of AEA
with NADA or NA5HT (Fig. 3a, b). Interestingly, we observed that
AEA potentiated the formation of 14′,15′-epoNADA (~2-fold) in a
concentration-dependent manner (Fig. 3a). Contrariwise, AEA
inhibited 14′,15′-epoNA5HT formation (~0.5-fold) (Fig. 3b). It is
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Fig. 2 Targeted lipidomics for measuring eVDs and epoxy-eVDs. a Authentic standards 14’,15’-epoNADA and 14’,15’-epoNA5HT were synthesized. (i) mCPBA, RT, 1 h, MeCN (ii) reverse-phase HPLC purify (iii) EDC, DMAP, DIPEA; ice bath 1 h; RT 8 h; 50:50 DCM:DMF (iv) reverse-phase HPLC purify.
b Development of LC-MS/MS method for the separation of NADA, epo-NADA, NA5HT, epo-NA5HT and AEA (Method 1) and the different regioisomers
of EET-EAs and epo-NADA and epo-NA5HT (Method 2). AEA m/z 348.3 → m/z 203.2; NADA m/z 440.2 → m/z 287.1; 14’,15’-epoNADA m/z 456.3 →
m/z 137.1; 14’,15’-epoNA5HT m/z 479.3 → m/z 160.1; NA5HT m/z 463.3 → m/z 287.2; EET-EA m/z 264.2 → m/z 62.0. c NADA and NA5HT metabolism
by BV2 microglial cells under lipopolysaccharide (LPS) stimulation in the presence of 1 µM t-AUCB (sEH inhibitor) and 10 µM NADA or NA5HT. The
reversible CYP epoxygenase inhibitor SKF 525A was used to demonstrate CYP-mediated metabolism. Data represents the mean ± SEM of three
experiments. Statistical signiﬁcance based on a two-tailed t-test with equal variance. All data can be found in the Source Data ﬁle.

possible that AEA acts as a potentiator of CYP-mediated NADA
metabolism and an inhibitor of CYP-mediated NA5HT metabolism, either directly or indirectly. Several ligands have shown to
either act as direct potentiators or inhibitors of CYP metabolism
through cooperative or allosteric binding41,42. To explore this
possibility, we delineated the mechanism of eVD metabolism using
a recombinantly expressed CYP.
Of the common CYP epoxygenases in mouse, CYP2J9 and
CYP2J12 were shown to be highly expressed in mouse brain
tissues while CYP2Cs showed low expression43. We conﬁrmed
that CYP2J9 and CYP2J12 are expressed in the BV2 microglial
cells used for our studies (Supplementary Fig. 6). CYP2J9 and
CYP2J12 are highly homologous to human CYP2J2. Hence, we
4

elucidated the biochemistry of eVD metabolism in the presence
and absence of AEA by human CYP2J2.
Formation of epoxy-eVDs by human CYP2J2. CYP2J2 is highly
expressed in the brain, cardiovascular, and cerebrovascular systems and is one of the major epoxygenases in these tissues44,45.
Additionally, CYP2J2 is known to epoxidize several endocannabinoids including AEA32,35,46. In order to study the direct
metabolism of NADA and NA5HT, we incubated CYP2J2 with
each eVD and detected the metabolites using UV–Vis highperformance liquid chromatography (HPLC) and LC-MS/MS.
All of the oxidized products of NADA (PD1-11) and NA5HT
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Fig. 3 Potentiation of eVD metabolism by AEA. a Metabolism 10 µM NADA and b 10 µM NA5HT in the presence of increasing concentrations of AEA by
BV2 microglia. Metabolism was conducted similarly to data in Fig. 2c. Data shown are the mean ± SEM of n = 6 (two sets of triplicate performed on
separate days). Statistical signiﬁcance is based on a one-way ANOVA with a Tukey’s post-hoc. c Schematic of the CYP2J2-CPR-Nanodisc. d, e Metabolism
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(PS1-7) are detailed in the Supplementary Figs. 7–18 and Supplementary Table 2. We determined that 14′,15′-epoNADA
(PD5) is a product based on the fragmentation and co-elution
with the synthesized standard. PS2 was conﬁrmed to be 14′,15′epoNA5HT. As a comparison to eVDs, we also investigated CAP
as a substrate of CYP2J2, and found headgroup-oxidized products
among other oxygenated products (Supplementary Figs. 19–26
and Supplementary Table 2).
Kinetics of eVD metabolism by CYP2J2-CPR-Nanodiscs. We
next incorporated CYP2J2 and CPR into Nanodiscs (ND) and

proceeded to determine the kinetics of the 14′,15′-epoxide formation (Fig. 3). The metabolism of NA5HT by CYP2J2 is in a
similar range as the metabolism of AEA and other lipid
PUFAs,34,36 but the metabolism of NADA is low. Interestingly,
the data demonstrate the presence of multiple binding sites, as the
kinetics plots strongly deviate from a typical Michaelis-Menten
model. The plots resemble the beginning of a sigmoidal curve
indicating positive binding interactions. However, saturation was
not achieved as the eVDs are poorly metabolized and insoluble
beyond 100 µM (Fig. 3d and e). We therefore hypothesized that
there are at least two binding sites. To further probe the kinetics
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of eVD metabolism, we measured the rate of NADPH oxidation
by CYP2J2-CPR-ND in the presence of the eVDs. CPR shuttles
electrons from NADPH to CYPs to facilitate the metabolism of
substrates. Therefore, the rate of NADPH oxidation increases in
the presence of CYP substrates. In this case, NADPH oxidation in
the presence of NA5HT showed biphasic kinetics, which is
unique to this substrate as described in the supplementary section
(Supplementary Fig. 27).
Relative binding afﬁnities of NADA and NA5HT. As eCBs do
not produce substantial Soret shift upon binding, we used an
ebastine (EBS) competitive inhibition assay to measure the
binding afﬁnity of NADA and NA5HT47,48. Both NADA and
NA5HT displayed competitive inhibition of EBS binding (Eq. 2),
suggesting that the binding of NADA and NA5HT overlap the
binding of EBS (Ki for NADA is 71.1 ± 20.0 μM and Ki for
NA5HT is 49.3 ± 6.2 μM).
Co-metabolism of AEA with NADA or NA5HT. We next
determined the co-substrate kinetics of AEA with the eVDs to
determine if we can explain the observed effects of AEA on BV2mediated metabolism. We developed an LC-MS/MS method to
simultaneously measure the four different regioisomers of AEA
epoxides (EET-EAs) and either 14′,15′-epoNADA or 14′,15′epoNA5HT (Fig. 2b, Method 2). We had previously determined
the kinetics of AEA metabolism by CYP2J2-CPR-NDs34, and we
repeated these experiments using two concentrations (25 and 75
μM) of either NADA or NA5HT. NADA inhibited AEA metabolism following a competitive inhibition model (Fig. 3f). A 3D
global ﬁt of the data (Supplementary Fig. 28) yields a Ki of 7.50 ±
0.88 μM for the inhibition of AEA by NADA, which is among the
strongest endogenous inhibitors of CYP2J2 as compared to virodhamine49. NA5HT was a noncompetitive inhibitor (Eq. 3) at
25 μM (Ki = 21.4 ± 3.6 μM) and a competitive inhibitor at 75 μM
(Ki = 86.6 ± 18.5 μM) (Fig. 3g). NADA and NA5HT also altered
the regioselectivity of AEA epoxidation in a concentrationdependent manner (Supplementary Fig. 29). Interestingly, AEA
showed a biphasic potentiation of NADA and NA5HT metabolism (Fig. 3h, i) when we measured the epoxy-eVD formation.
Overall, the potentiation of eVD metabolism by AEA and the
altered AEA regioselectivity in the presence of eVDs demonstrate
that eVDs and AEA are binding to CYP2J2 at multiple sites. A
further analysis of this multiple-site binding is provided in the
Supplementary Note 2 and Supplementary Fig S30. Furthermore,
these data support the observed crosstalk of AEA and eVDs in
microglial cells (Fig. 3a, b), as at similar concentrations within
each experiment AEA potentiates NADA and inhibits NA5HT.
Molecular dynamics (MD) simulations of eVD binding to
CYP2J2. In order to characterize the molecular basis of the multisite kinetics observed with the eVDs, we performed MD simulations starting from membrane-bound structures of CYP2J2 in
complex with substrates (AEA, NADA or NA5HT). Initial
molecular docking was performed with AEA and either NADA or
NA5HT in a stepwise manner50. These models allowed us to
probe the binding mode of a second molecule to CYP2J2 in the
presence of another molecule bound in the active site in an
unbiased manner (i.e., without any assumptions about location of
peripheral binding pockets). Two distinct conﬁgurations of peripheral AEA binding, with either NADA or NA5HT in the active
site, were identiﬁed (Fig. 4a, b). In Conﬁguration 1, AEA was
docked in a pocket located below the I-helix, with its ethanolamine group near a residue (R321) that we have previously
identiﬁed to modulate PUFA binding36 (Fig. 4a). In Conﬁguration 2, AEA was located closer to the membrane interface
6

(Fig. 4b). For the two identiﬁed AEA binding conﬁgurations, the
initial orientation of NADA or NA5HT in the active site was
similar, with the main epoxidation site (carbons C14 and C15)
close to the heme moiety (distance <5 Å), and the headgroup (DA
or 5HT) pointing away from the heme. These docking results
suggested that NADA/NA5HT binding was not modulated by the
same PUFA-interacting residues previously reported (T318, R321
and S493)36. Owing to the larger headgroups of NADA/NA5HT
compared to other PUFAs (i.e., DA/5HT vs. carboxylic acid), a
different binding orientation (not interacting with the PUFA
triad) was necessary to ﬁt these molecules in the active site.
The MD simulations (Fig. 4c, Supplementary Tables 3–6, and
Supplementary Movies 1–4) revealed that stable NADA/NA5HT
binding (i.e., with the epoxidation site distance to the heme <5 Å)
was only achieved when AEA is bound in Conﬁguration 2
(Fig. 4b). When AEA is located in the I-helix pocket (Conﬁguration 1), NADA or NA5HT in the active site gradually move
away from the heme, which results in a displacement of its
epoxidation site (with the distance to heme between 7.5 and 10 Å
during the simulations) (Fig. 4c). In contrast, AEA in Conﬁguration 2 constrains the motion of NADA or NA5HT in the
active site, which maintain their potentially productive orientation close to the heme (epoxidation site to heme distance <5 Å)
during the simulation (Fig. 4c). In these simulations, the
ethanolamine group of AEA interacted with Q228, located near
the membrane interface, and remained locked in its binding site.
Positioning of AEA in turn constrained the mobility of the
molecule in the active site (NADA or NA5HT). NADA/NA5HT
are further stabilized by hydrophobic interactions (mainly with
F310) and transient electrostatic interactions (i.e., NA5HT
serotonin group with D307 and E222). These observations
suggest that NADA/NA5HT binding is enhanced by concurrent
AEA binding to a peripheral site near the membrane interface
and provide insights into the protein residues involved in this
binding (e.g., Q228 for AEA and F310 for NADA/NA5HT).
Overall, the MD simulations in conjunction with the kinetics data
concur with the observations from the cell culture studies that
AEA enhances the metabolism of NADA.
Anti-inﬂammatory action of eVDs in microglial cells. We
further proceeded to characterize their pharmacology. Previous
studies have demonstrated the anti-inﬂammatory actions of
eVDs51–53; thus, we hypothesize that epoxy-eVDs would also be
anti-inﬂammatory. Microglial cells are strongly activated after
injury and release pro-inﬂammatory cytokines such as IL-6, IL1β, and TNF-α. Therefore, there is a signiﬁcant interest in discovering lipid-based molecules that decrease microglial activation. To investigate the actions of eVDs and epoxy-eVDs, we
measured the levels of pro-inﬂammatory nitric oxide (NO), IL-6,
IL-1β, and TNF-α in lipopolysaccharide- (LPS)-stimulated BV2
cells. All eVDs and epoxy-eVDs dose-dependently reduced NO
and IL-6 production (Fig. 5a–d) and the IC50 values are tabulated
in Table 1. Together, these data demonstrate that the eVDs and
the epoxy-eVDs are anti-inﬂammatory mediators. As determined
by MTT and BrdU assays, these compounds were not toxic at
their effective concentrations, though NA5HT and 14′,15′-epoNA5HT increased cell viability in the presence of LPS, suggesting
they may be pro-proliferative, which was conﬁrmed using a BrdU
assay (Supplementary Fig. 31, 32).
We also measured the mRNA expression of Il-6, Il -10, Il -1β,
and Tnf-α to determine the inﬂammatory phenotype. Whereas
IL-6, IL -1β, and TNF-α are pro-inﬂammatory, IL-10 is an antiinﬂammatory cytokine that facilitates the resolution of inﬂammation. Concentrations around the IC50 of the IL-6 and NO
experiments (1 and 2.5 µM of each compound) were tested and
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Configuration 1
CYP2J2

Configuration 2
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NA5HT
F310
AEA

AEA
Q228

NA5HT

D307
R321
F310
NADA

membrane

AEA
AEA

Q228

NADA

c

Fig. 4 Concurrent CYP2J2 binding of AEA and NADA/NA5HT in MD simulations. Representative snapshots of two distinct conﬁgurations of AEA and
NADA/NA5HT identiﬁed with molecular docking and with MD simulations: a peripheral binding pocket located near helix I (shown in purple cartoon) and
b peripheral binding site near the membrane interface. In both panels, peripheral and active binding site cavity are shown as orange and blue surfaces,
respectively. Lipids are shown in stick representation and CYP2J2 in cartoon representation. AEA, NADA, and NA5HT molecules are shown as sticks.
Notable residues involved in AEA/NADA/NA5HT interactions are also shown as sticks. Carbons involved in epoxidation are highlighted as green spheres.
c Time series of carbon-to-heme distances obtained from 50 ns MD simulations for the main epoxidation sites of NADA/NA5HT. Colors correspond to the
subpanels shown in a and b.

compared to cells with LPS only. All the eVDs and epoxy-eVDs
downregulated pro-inﬂammatory Il-6, Il-1β, and Tnf-α with
14′,15′-epo-NA5HT being the most effective overall (Fig. 5e–g).
NADA and 14′,15′-epoNADA concomitantly upregulated Il-10
(Fig. 5h).
Most eCBs and eVDs mediate anti-inﬂammation and anti-pain
poly-pharmacologically through CB1, CB2, and TRPV1 receptors.
We determined that the mRNA of Cnr1 (CB1 gene), Cnr2 (CB2
gene), and Trpv1 are expressed in the BV2 cells (Supplementary
Fig. 33). Since these receptors are known targets of eVDs and
mediate inﬂammation and pain, we proceeded to measure the
activation of CB1, CB2, and TRPV1 by epoxy-eVDs.
Activation of TRPV1 by eVDs and epoxy-eVDs. Previous studies have shown that NADA mediates anti-inﬂammation via
TRPV151. As TRPV1 is a non-selective cation channel, activation
was determined by measuring the relative Ca2+ inﬂux

(Supplementary Fig. 34 and Table 1). We determined that NADA
and 14′,15′-epoNADA are full agonists, with ~80% activation
compared to CAP (Fig. 5i). The EC50 of 14′,15′-epoNADA is
about 6-fold tighter than NADA. 14′,15′-epoNADA also promoted a broader duration of Ca2+ inﬂux opening compared to
NADA (Supplementary Fig. 34). The TRPV1-selective antagonist
AMG-9810 was able to fully antagonize the signal from CAP, the
eVDs, and the epoxy-eVDs, conﬁrming the Ca2+ inﬂux is
TRPV1-mediated (Supplementary Fig. 35b, c).
On the contrary, 14′15′-epoNA5HT was found to be a partial
agonist of TRPV1 up to 250 nM, with a 24% activation compared
to CAP (Fig. 5j). This signal was antagonized by AMG-9810,
demonstrating it is TRPV1-mediated (Supplementary Fig. 35c).
Concentrations above 250 nM, however, resulted in a reduction of
the signal, signifying that 14′,15′-epoNA5HT is an antagonist of
TRPV1 at higher concentrations (Fig. 5j). Previously, NA5HT
had been shown to be an antagonist of TRPV127; therefore, we
measured the antagonism of TRPV1 by 14′15′-epoNA5HT and
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Fig. 5 Anti-inﬂammatory actions of eVDs and receptor activation. a–d Anti-inﬂammatory effects of eVDs and epoxy-eVDs were determined by
preincubating eVDs and epoxy-eVDs with BV2 cells for 4 h prior to stimulation by 25 ng mL−1 LPS. Data represents the mean ± SEM of n = 3 independent
experiments. a Dose-dependent inhibition of nitric oxide (NO) production by NA5HT and 14,15-epoNA5HT as determined by Griess Assay. b Dosedependent reduction of IL-6 protein expression (ELISA) by NA5HT and 14,15-epoNA5HT. c Dose-dependent inhibition of NO production and (d) IL-6
protein expression by NADA and 14,15-epoNADA. e–h Anti-inﬂammation experiments were repeated to measure pro-inﬂammatory Il-6, Il-1β, and Tnf-α
and anti-inﬂammatory Il-10 mRNA expression in the presence of LPS. Data represents the average of three technical replicates. Data is reported as the
mean relative expression. i–k eVD activation to TRPV1-transfected HEK cells was determined using a Fura 2-AM Ca2+-inﬂux assay. The Bmax of capsaicin
(CAP) activation is deﬁned as 100%. Data represents the mean ± SEM of n = 6 (two sets of triplicate experiments on separate days). k Antagonism was
determined by preincubating cells with antagonist prior to stimulating with 250 nM CAP. l–n eVD activation of CB1 and CB2 was determined by the
PRESTO-Tango assay. Bmax of CP-55940 is deﬁned as 100%. Data represents the mean ± SEM of n = 6 (two sets of triplicate experiments on separate
days). All data can be found in the Source Data ﬁle.
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DNBd
DNBd
8.80 ± 5.57
DNBd

compared it to NA5HT. 14′15′-epoNA5HT functioned as an
antagonist of CAP at all concentrations, with an IC50 of 250 ±
38 nM (Fig. 5k). Of note, this IC50 correlates to the concentration
at which the self-antagonism was observed for 14′,15′-epoNA5HT (Fig. 5j). From Table 1, we see that 14′15′-epoNA5HT is
a 30-fold stronger antagonist of TRPV1 than NA5HT.

----19.2 ± 3.4
---

Activation of CB1 and CB2 by eVDs and epoxy-eVDs. We next
determined the activation of CB1 and CB2 by eVDs and the epoxyeVDs using the PRESTO-Tango assay32. Herein, NADA, 14′,15′epoNADA, and 14′,15′-epoNA5HT, but not NA5HT, demonstrated
full-agonist activation of CB1 (~100% activation as compared to
CP55940) (Fig. 5l, m, Table 1). Of these, NADA activates CB1 2fold more potently as compared to 14′,15′-epoNADA. 14′,15′epoNA5HT activated CB1 with an EC50 of 16.5 ± 11.7 nM. Only
NA5HT activated CB2. The measured EC50 was 8.80 ± 5.57 nM
with 19.2% activation compared to CP55940, which makes it a
partial agonist.
We further tested agonism and antagonism of NA5HT,
NADA, 14′,15′-epoNADA, and 14′,15′-epoNA5HT on CB1 and
CB2 receptors. None of these antagonized 50 nM CP55940
activation of these receptors (Supplementary Fig. 36c). Therefore,
NA5HT does not act on CB1, and NADA, 14′,15′-epoNADA, and
14′,15′-epoNA5HT do not act on CB2. This interesting
dichotomy could be exploited to design pain therapeutics that
speciﬁcally target one receptor. Overall, our data shows that
14′,15′-epoNA5HT is anti-inﬂammatory, is an agonist of CB1,
and is an antagonist of TRPV1, thereby making it the most
efﬁcacious of the eVDs for the development of pain therapeutics.

aPercent activation compared to the B
maxc of CAP.
bnM.
cPercent activation compared to the B
maxc of CP-55940.
dDNB: does not activate. Compounds upto 1 μM in concentration

do not agonize the receptor and do not antagonize 50 nM of CP-55940.

0.045 ± 0.01
0.080 ± 0.03
DNBd
16.5 ± 11.7
83.9 ± 9.2
92.3 ± 11.2
--99.9 ± 13.1
962 ± 249
156 ± 36
(7,650 ± 1,300)
120 ± 27 (254 ± 38)
NADA
14’,15’-epoNADA
NA5HT
14’,15’-epoNA5HT

0.909 ± 0.076
0.888 ± 0.135
2.14 ± 0.06
2.07 ± 0.18

0.507 ± 0.065
0.807 ± 0.440
1.06 ± 0.49
1.56 ± 0.22

83.8 ± 13.6
79.7 ± 9.8
--23.6 ± 4.4 ---

CB1 % activationc
TRPV1 EC50 (IC50)b
TRPV1 % activationa
IL-6 expression IC50 (μM)
NO production IC50 (μM)

Table 1 Anti-inﬂammatory marker inhibition and receptor activation parameters of eVDs and epoxy-eVDs.

CB1 EC50b

CB2 % activationc

CB2 EC50b
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Inhibition of TRPV1 responses in primary DRG neurons. To
further determine if NA5HT and 14′,15′-epoNA5HT could inhibit
native TRPV1 expressed in mouse dorsal root ganglia (DRG)
neurons, we compared CAP-evoked intracellular free Ca2+ ([Ca2
+] ) response in cultured mouse DRG neurons with and without
i
pretreatment of NA5HT and 14′,15′-epoNA5HT using live-cell
Ca2+ imaging. Bath application of CAP at 250 nM produced a
robust [Ca2+]i increase in 47.12% ± 2.18% of DRG neurons
(Fig. 6a, d). However, after pretreatment of 1 μM NA5HT or 1 μM
14′,15′-epoNA5HT for 10 min, 250 nM CAP could only activate
33.64% ± 1.16% and 20.01% ± 2.39% of DRG neurons, respectively
(Fig. 6b–d). Consistent with the reduced number of DRG neuron
activated by CAP after pretreatment of NA5HT and 14′,15′-epoNA5HT, the amplitude of CAP-induced [Ca2+]i increase was also
signiﬁcantly diminished after pretreatment of NA5HT and 14′,15′epoNA5HT (Fig. 6b, c, e). We also examined the inhibitory effect
of NA5HT and 14′,15′-epoNA5HT on CAP-induced excitation of
DRG neurons by using current-clamp recording. Consistent with
Ca2+ imaging results, CAP evoked a large membrane potential
depolarization and robust action potential ﬁring, which was also
signiﬁcantly inhibited by pretreatment with NA5HT or 14′,15′epoNA5HT for 10 min (Fig. 6f–i). Of note, inhibition of TRPV1mediated [Ca2+]i increase membrane potential depolarization by
14′,15′-epoNA5HT was signiﬁcantly stronger than that produced
by NA5HT (Fig. 6i), which is consistent with results in TRPV1expressing HEK293 cells. Together, these results suggest that both
NA5HT and epoNA5HT are potent TRPV1 antagonists suppressing TRPV1 function in both heterologous cells and native DRG
neurons.
Discussion
There is evidence that there is a synergism between the eCB and
the opioid system that reduces the need for high doses of
opioids7. Hence, it is important to understand the function of
eCBs and their metabolites as endogenous and exogenous ligands
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Fig. 6 Inhibition of CAP-induced response in cultured mouse DRG neurons. a–c Ratiometric Ca2+ imaging of cultured wild-type mouse DRG neurons.
Each trace corresponds to ﬂuorescence in a single neuron. CAP elicited large [Ca2+]i responses in cultured DRG neurons (a), which was signiﬁcantly
inhibited by pretreatment of NA5HT (b) and 14’,15’-epoNA5HT (c) for 10 min, respectively. d Percentage of DRG neurons responding to CAP with or
without pretreatment of NA5HT or 14’,15’-epoNA5HT. (n = 5 from 4 mice; error represents SEM). P-values: 0.0012 (**) NA5HT+CAP vs. Vehicle+CAP,
0.0011 (**) NA5HT+CAP versus 14’, 15’-epoNA5HT+CAP, and < 0.0001 (****). e Quantiﬁcation of CAP-induced [Ca2+]i response with or without
pretreatment of NA5HT or 14’,15’-epoNA5HT. (n = 5 from 4 mice; error represents SEM). P-values: 0.0035 (**), 0.0003 (***), and < 0.0001 (****). (f)
Representative traces showing CAP-induced a robust membrane depolarization and action potential ﬁring in cultured DRG neurons, which was signiﬁcantly
inhibited by pretreatment of NA5HT (g) and 14’,15’-epoNA5HT (h) for 10 min, respectively. i Summarized data showing that CAP-produced membrane
depolarization and action potential ﬁring in DRG neurons with or without pretreatment of NA5HT or 14’,15’-epoNA5HT. (n = 5 from three mice; error
represents SEM). Drug concentration: CAP, 250 nM; NA5HT, 1 μM; 14’,15’-epoNA5HT, 1 μM; and KCl, 100 mM. P-values: 0.0057 (**), and <0.0001 (****).
(one-way ANOVA followed by a Tukey’s post-hoc analysis). All data can be found in the Source Data ﬁle.

of the receptors that are involved in pain response modulation.
It has been previously shown that the activation of CB1 and
CB2 is associated with anti-nociceptive and anti-inﬂammatory
actions10,54. Regulation of TRPV1 can also modulate pain by
mostly antagonizing TRPV1. While there are ample examples of
drugs that target cannabinoid receptors or TRPV1, there is dearth
of molecules that are rheostat regulators (varying strength of
agonism or antagonism) of both cannabinoid receptors and
TRPV1. The primary difference between many drugs and
10

endogenous lipids is that the former are usually structurally rigid
and target either CB receptors or TRPV1 whereas the latter are
functionally plastic and capable of activating both receptors.
NADA and NA5HT are AA derivatives of neurotransmitters.
NADA is an agonist of both CB1 and TRPV126,55. NA5HT is an
antagonist of TRPV1. PUFAs, through parallel pathways, are
converted into epoxide mediators that have been shown to reduce
pain30. Overall, there is strong evidence for pain modulation by
eCB and PUFA epoxides through multiple receptors.
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Fig. 7 Summary of the eVD metabolism pathway and pharmacology. The eVDs bind in a two-site model to CYP2J2 and other epoxygenases and are
metabolized to form epoxy-eVDs. AEA potentiates the metabolism of eVDs as revealed by BV2 metabolism assays, in vitro CYP2J2 kinetics, and molecular
dynamics simulations. 14’,15’-epoNADA is a better TRPV1 agonist and slightly weaker CB1 agonist compared to NADA. 14’,15’-epoNA5HT is a better TRPV1
antagonist compared to NA5HT, and is a CB1 full agonists as opposed to NA5HT, which is a partial CB2 agonist. Overall, the eVDs and epoxy-eVDs
potently downregulate pro-inﬂammatory NO production and Il-6, Il-1ß, and Tnf-α expression while increasing Il-10 expression, thereby demonstrating that
they are potently anti-inﬂammatory.

Using a combined biophysical and cell-based approach, we
report the pharmacological characterization of NADA and
NA5HT epoxides that are produced by the CYP epoxygenase
pathway in microglial cells. These molecules are antiinﬂammatory and function through the eCB-TRPV1 axis. These
results can potentially inspire new therapeutics that effectively
target this axis. The overall ﬁndings of this work are outlined in
Fig. 7 and discussed below.
The biosynthesis of the epoxy-eVDs is facilitated by CYP
epoxygenases as the inhibiton of CYP enzymes in microglial cells
reduce the levels of these metabolites. In the pig brain, we were
able to detect the parent compounds NADA and NA5HT, whose

levels were much lower and variable than that of AEA. The
epoNADA and epoNA5HT were spontaneously formed by
microglia cells in the presence and absence of inﬂammatory stimulus. As the levels of AEA were high and eVDs were low, we
tested the effect of eVD metabolism by CYPs in the presence of
AEA. Interestingly, the metabolism of NADA is potentiated by
AEA in the microglial cells. This was an interesting observation as
there are very few examples where the binding of one ligand at
the enzyme active site potentiates the metabolism of another
ligand. However, such complicated substrate interactions are
common for CYPs with a large active sites such as
CYP3A441,42,56. We demonstrate that AEA is a complicated
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effector of eVD metabolism in CYP2J2, which potentially explains
the observed potentiation of NADA metabolism in BV2 cells.
However, AEA may also be inhibiting unknown enzymes that
degrade NADA or 14′,15′-epoNADA.
We then proceeded to investigate the the interactions of AEA
and the eVDs at the enzymological level to gain better molecular
insight into the metabolism. CYP2J9, CYP2J12, and CYP2J2 were
all shown to be highly expressed in mouse and human
brains43,44,57–59. Additionally, CYPs such as CYP2J6 are expressed in DRGs and is involved in the epoxidation of lipids that act
on TRPV1 when paclitaxel is administered. In addition, CYP2J4
is found in TRPV1-positive rat trigeminal ganglia, which are also
involved in pain-temperature sensing pathways60. Comparing the
in cellulo metabolism data to the in vitro kinetic measurements
with CYP2J2-NDs reveals a complex network of substratesubstrate interactions. Previously, we determined that PUFAs
bind CYP2J2 at two main sites: the substrate access channel and
the PUFA binding pocket36. AEA binds to CYP2J2 with PUFAlike properties: that is, by binding similar sites in the substrate
access channel and PUFA binding pocket. However, NADA and
NA5HT do not bind the PUFA binding pocket and have unstable
binding to the substrate access channel. Therefore, AEA can
simultaneously be accommodated in binding to CYP2J2. The MD
simulations support that up to three overlapping binding sites are
possible, which can help to explain the observed complex AEA
and eVD interactions, such as the regioselectivity change in the
AEA metabolites (Supplementary Fig. 29) and the potentiation of
eVD metabolism (Figs. 3 and 4). We have previously observed
complex inhibition and regioselectivity changes for endogenous
substrates of CYP2J234,49,50; however, this is the ﬁrst report of a
potentiation of CYP2J2 metabolism. Overall, the ﬁnding implies
that the co-substrate AEA potentiates the metabolism of NADA
and NA5HT by CYP2J2 in vitro. Therefore, this study provides
another therapeutic route where drugs can potentiate CYP2J2’s
epoxidation of endogenous lipids.
One common observation is that the oxidized eVD metabolites
exhibit different pharmacology compared to the parent molecules. CYP2U1 metabolizes NA5HT to a 2-oxo derivative that is a
weaker FAAH inhibitor compared to NA5HT24. NADA was
shown to be hydroxylated at the ω and ω-1 positions by rat liver
microsomes, which were weaker TRPV1 agonists compared to
NADA26. Therefore, the 2-oxo-NA5HT and NADA-OH metabolites may represent a degradation pathway of NADA and
NA5HT. However, we show that the epoxy-eVDs are potently
anti-inﬂammatory molecules in activated microglial cells.
A key observation is that the epoxidation of eVDs increases
their activity on TRPV1. 14′,15′-epoNADA is a 6.5-fold stronger
agonist than NADA and 14′,15′-epoNA5HT is a 30-fold stronger
antagonist than NA5HT at TRPV1, while also showing partial
agonism at lower concentrations. Moreover, both NA5HT and
14′,15′-epoNA5HT suppressed TRPV1-mediated [Ca2+]i response
and membrane potential depolarization in mouse DRG neurons
with 14′,15′-epoNA5HT exerting a signiﬁcantly stronger inhibition of TRPV1-mediated responses than that produced by
NA5HT. Based on the cryo-EM structure of TRPV1, it has been
proposed that agonists binding at the CAP-binding pocket facilitate channel opening by promoting the lateral movement of the
S4-S5 linker61. The epoxide could be forming some interactions
with H-bond donating groups such as Tyr or Asp residues that
populate this linker, which facilitates the channel opening. Since
TRPV1 exists as a tetramer, the binding of 14′,15′-epoNA5HT to
different sites and perhaps different monomers may help to
explain its dual agonism/antagonism. However, since the activation of TRPV1 is self-antagonized at concentrations greater than
250 nM (around the IC50), the 14′,15′-epoNA5HT functions
overall as an antagonist.
12

The epoxidation of NA5HT changes it from being a partial
CB2 agonist to a full CB1 agonist. This is intriguing given that
14′,15′-epoNA5HT and NA5HT differ only by an epoxide.
Contrariwise, the epoxidation of NADA does not greatly alter
their potency towards CB1 receptor activation. Previously it was
shown that the epoxidation of omega-6 and omega-3 eCBs have
preferential activation towards CB232,46. Herein, we show that
eVD epoxides target CB1 receptors. While NADA and 14′,15′epoNADA are TRPV1 and CB1 agonists, NA5HT and 14′,15′epoNA5HT are TRPV1 antagonists. The complex functional
crosstalk of CB1 and TRPV1 is still being elucidated,47,62 but the
studies suggest that the plasticity exhibited by endogenous lipids
indirectly contributes to this crosstalk.
Overall, the eVDs and epoxy-eVDs lower pro-inﬂammatory
cytokines while increasing anti-inﬂammatory IL-10. They also
potently activate cannabinoid receptors and are potent ligands of
TRPV1. The epoxidation of eVDs increases their potency at
TRPV1 and alters their pharmacology at cannabinoid receptors.
In particular, 14′,15′-epoNA5HT is the most effective epoxy-eVD
at reducing pro-inﬂammatory markers. 14′,15′-epoNA5HT is also
a potent antagonist of TRPV1 expressed in either HEK293 cells or
native DRG neurons and a potent full agonist of CB1. Lastly, the
formation of epoxy-eVDs by CYPs is potentiated by the cosubstrate AEA, which is also metabolized by CYPs to form EETEA that are potent CB2 ligands. Hence, inﬂammation and related
pain response is accompanied by a storm of epoxy-eVDs and
epoxy-eCBs that are multi-faceted endogenous molecules capable
of inﬂuencing the activity of CB1, CB2 and TRPV1 receptors. The
discovery of these molecules will serve as templates for new
multi-target therapeutic drugs that will prove useful for the
treatment of inﬂammatory pain, as well as of other conditions in
which these receptors are targeted in other clinical studies.
Methods
Materials and methods concerning RT-qPCR, IL-6 ELISA kit-based detection,
Griess Assay to detect nitric oxide, cell viability assay using MTT, cell proliferation
assay using BrdU, protein expression and puriﬁcation methods, nanodisc assembly,
in vitro lipid metabolism, and full-scan mass spectrometry analysis of the metabolites can be found in the supplementary information.
Synthesis of NADA and NA5HT. Dopamine hydrochloride (24.9 mg, 0.131 mmol,
2.0 equiv.) or serotonin hydrochloride (27.9 mg, 0.131 mmol, 2.0 equiv.) was added to
N,N-diisopropylethylamine (DIPEA, 27.4 μL, 0.145 mmol, 2.2 equiv.) in an anhydrous
solution of DMF/CH2Cl2 (1/1 v/v, 25 mL) under an argon atmosphere. This mixture
was cooled in an ice-water bath and then AA (21.7 μL, 0.066 mmol, 1.0 equiv.), 1ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC, 63 mg, 0.33 mmol, 5.0 equiv.),
and 4-dimethylaminopyridine (DMAP, 2 mg, 0.0099 mmol, 0.15 equiv.) were added.
After 1 h, the reaction was warmed to room temperature and allowed to incubate at the
same temperature for 8 h. Afterwards, toluene was added, and the reaction was concentrated under reduced pressure. The product was extracted 3× from water with
CH2Cl2 and then washed 1× with brine. The organic layer was dried over sodium
sulfate and concentrated under reduced pressure to yield a yellow-brown oil. NADA
[(5Z,8Z,11Z,14Z)-N-(3,4-dihydroxyphenethyl)icosa-5,8,11,14-tetraenamide] and
NA5HT [(5Z,8Z,11Z,14Z)-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)icosa-5,8,11,14-tetraenamide] were puriﬁed using HPLC Method 2 below. Products were dried under
reduced pressure, stored in ethanol, and quantiﬁed via HPLC as stated below. Yields
were 13.0 mg NADA (45%) and 12.8 mg NA5HT (45%). [NADA] 1H-NMR (400
MHz, CDCl3) δ 6.96 (s, 1H); 6.80 (d, J = 8.0 Hz, 1H); 6.74 (d, J = 2.0 Hz, 1H); 6.58
(dd, J = 8.1, 2.0 Hz, 1H); 5.61 (s, 1H); 5.54 (d, J = 6.5 Hz, 1H); 5.44–5.27 (m, 8H); 4.12
(q, J = 7.1 Hz, 1H) (ethyl acetate); 3.48 (q, J = 6.7 Hz, 2H); 2.88–2.75 (m, 6H) (part
ethyl acetate); 2.70 (t, J = 7.1 Hz, 2H); 2.19–2.12 (m, 2H); 2.12–1.99 (m, 6H); 1.68 (p,
J = 7.4 Hz, 2H); 1.41–1.19 (m, 8H) (part ethyl acetate); 0.88 (t, J = 6.7 Hz, 3H). HRMS
(m/z): [M + H+] cal’d 440.3165, observed 440.3161 (−0.9 ppm); C28H42NO3.
[NA5HT]. 1H-NMR (500 MHz, CDCl3) δ 7.90 (s, 1H); 7.04–6.98 (m, 2H); 6.82–6.76
(m, 1H); 5.53 (s, 1H); 5.44–5.29 (m, 8H); 3.57 (q, J = 6.6 Hz, 2H); 2.90 (t, J = 6.8 Hz,
2H); 2.80 (dt, J = 18.2, 5.9 Hz, 6H); 2.08 (ddt, J = 31.1, 14.6, 7.4 Hz, 6H); 1.73–1.63
(m, 2H); 1.40–1.16 (m, 7H) (part ethanol); 0.88 (t, J = 6.7 Hz, 3H). HRMS (m/z):
[M + H+] cal’d. 463.3325, observed 463.3322 (−0.6 ppm); C30H43N2O2.
Synthesis of 14′,15′-epoNADA and 14′,15′-epoNA5HT. Synthesis of EETs was
performed using m-chloroperoxybenzoic acid (m-CPBA) according to our previously established protocol32. AA (54.3 µL, 0.165 mmol, 1.0 equiv.) was combined
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with mCPBA (, 0.33 mmol, 2.0 equiv.) in 2 mL dichloromethane (DCM) and
allowed to react at room temperature for 1 h. The reaction was terminated with an
equivolume solution of 10% NaHCO3 (aq) and the aqueous layer was re-extracted
thrice with DCM. The organic layers were combined and resuspended with acetonitrile for reversed-phase HPLC separation [Mobile Phase A 95:4.9:0.1 H2O:
acetonitrile:acetic acid; Mobile Phase B 95:4.9:0.1 acetonitrile:H2O:acetic acid;
linear gradient, 50% Solvent B to 100% Solvent B over 1 h using a SunFireTM Prep
C18 OBDTM (see below)] of the terminal epoxide (14,15-EET) from the other
regioisomers. Yield: 4–8 mg of 14,15-EET (7.6-15% yield). 14,15-epoNADA
[(5Z,8Z,11Z)-N-(3,4-dihydroxyphenethyl)-13-(3-pentyloxiran-2-yl)trideca-5,8,11trienamide] and 14,15-epoNA5HT [(5Z,8Z,11Z)-N-(2-(5-hydroxy-1H-indol-3-yl)
ethyl)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienamide] were synthesized by
coupling DA and 5HT to 14,15-EET using the above coupling method. Yield from
14,15-EET: 3.6 mg (65%) 14′,15′- epoNADA, 4.7 mg (40%) 14′,15′-epoNA5HT.
[14′,15′-epoNADA] 1H-NMR (400 MHz, CDCl3) δ 6.80 (d, J = 8.1 Hz, 1H); 6.72
(s, 1H); 6.58 (d, J = 7.9 Hz, 1H); 5.81 (s, 1H); 5.65–5.25 (m, 6H); 3.47 (q, J = 6.5 Hz,
2H); 3.01 (d, J = 5.4 Hz, 1H); 2.80 (d, J = 20.6 Hz, 4H); 2.69 (t, J = 6.8 Hz, 2H); 2.45
(m, J = 7.3 Hz, 1H); 2.24 (m, J = 6.8 Hz 1H); 2.17–1.92 (m, 4H); 1.79–1.62 (m, 2H);
1.34 (q, J = 5.1, 3.7 Hz, 4H); 0.98–0.77 (m, 3H). HRMS (m/z): [M + H+] cal’d.
456.3114, observed 456.3104 (−2.2 ppm); C28H42NO4. [14′,15′-epoNA5HT] 1HNMR (500 MHz, CDCl3) δ 7.97 (s, 1H); 7.13–6.89 (m, 2H); 6.79 (dd, J = 8.7,
2.5 Hz, 1H); 5.60 (s, 1H); 5.55–5.29 (m, 7H); 5.23 (s, 1H); 3.56 (p, J = 8.1, 7.3 Hz,
2H); 2.96 (d, J = 7.2 Hz, 2H); 2.89 (q, J = 7.0 Hz, 2H); 2.79 (dt, J = 23.0, 6.3 Hz,
4H); 2.42 (d, J = 6.7 Hz, 1H); 2.21 (dt, J = 13.8, 6.8 Hz, 1H); 2.09 (dq, J = 20.9,
7.4 Hz, 4H); 1.68 (p, J = 7.6 Hz, 2H); 1.47–1.19 (m, 6H), 0.89 (d, J = 7.1 Hz, 3H).
HRMS (m/z): [M + H+] cal’d. 479.3274, observed 479.3269 (−1.0 ppm);
C30H43N2O3.
Extraction of NADA and NA5HT from porcine brain regions. Porcine brains
were obtained from freshly slaughtered swine from the Meat Science Laboratory at
the University of Illinois at Urbana-Champaign (Ryan Dilger Lab). The swine are
from a commercial swine line for the swine industry (1050 Cambro line) and were
fed a standard diet. The brains were dissected into regions (cerebellum; central core
comprising the hippocampus, hypothalamus, and thalamus; and the cerebrum
containing the cerebral cortex) and diced immediately after removal from the pig.
The tissue was then ﬂash frozen and stored at −80 °C until used. For extraction, the
tissue was homogenized in 5 volumes of ice-cold methanol (MeOH) containing
0.03 mm of the soluble epoxide hydrolase inhibitor 4-[[trans-4-[[(tricyclo
[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]cyclohexyl]oxy]-benzoic acid (t-AUCB)
and 1 mm of FAAH inhibitor phenylmethylsulfonyl ﬂuoride (PMSF). Debris was
ﬁltered using a ﬁlter column. The extract was then dried under reduced pressure
and resuspended in 50% MeOH. The extracts were then loaded onto 1-gram Bond
Elut C-18 cartridges (Varian, Harbor City, CA) (one column per gram of tissue),
preconditioned with 25% MeOH. Cartridges were washed with 4 mL of 10%
MeOH and eluted with 4 mL of 100% acetonitrile (MeCN). The eluates were dried
under reduced pressure in amber vials and stored under Ar(g) at −80 °C until
resuspended in 150 μL of 180-proof ethanol for LC-MS/MS analysis (the day after).
Samples of tissue were spiked with 1 µg of NADA or NA5HT standards to test the
recovery of this method, and we were able to recover 40% of the material.
HPLC analysis of NADA, NA5HT, and metabolites. Compounds were analyzed
and separated via HPLC consisting of an Alliance 2695 analytical separation
module (Waters, Milford, MA) and a Waters 996 photodiode diode array detector
(Waters). Synthesis puriﬁcation of EETs and epoxy-eVDs were separated in
reverse-phase using a SunFireTM Prep C18 OBDTM 5 μm 19 × 50 mm column
(Waters) and a 3.0 mL min−1 ﬂow rate, and for quantiﬁcation using a Phenomenex
Prodigy® 5μm ODS-2, 150 × 4.60 mm column (Phenomenex, PN 00F-3300-E0,
Torrance, CA) with a 1 mL min−1 ﬂow rate. Mobile Phase A consisted of 95:5%
H2O (0.1% acetic acid):MeCN and Mobile Phase B consisted of 5:95% H2O (0.1%
acetic acid):MeCN. A full-scan method (Method 1) was developed to investigate all
potential products from in vitro enzyme reactions as follows: 0–1 min, 100% A;
1–60 min, linear gradient of 100% A to 100% B; 60–65 min, 100% B. NADA and
NA5HT elution times were conﬁrmed using authentic standards (59.5 min and 60
min, respectively). A shorter method (Method 2) was developed to analyze the
hydrophobic products and for synthesis puriﬁcation and quantiﬁcation. 0–30 min:
100% A to 100% B; 30–40 min: 100% B. All wavelengths from 190–600 nm were
monitored. 14′,15′-epoNADA and 14′,15′-epoNA5HT were quantiﬁed at 281 nm
and 277 nm wavelengths, respectively, using a NADA and NA5HT standard curve,
respectively.
LC-MS/MS quantitation of NADA, NA5HT, and AEA from tissue. Samples
were analyzed with the 5500 QTRAP LC/MS/MS system (Sciex, Foster City, CA) in
Metabolomics Lab of Roy J. Carver Biotechnology Center, University of Illinois at
Urbana-Champaign. Software Analyst 1.6.2 was used for data acquisition and
analysis. The 1200 series HPLC system (Agilent Technologies, Santa Clara, CA)
includes a degasser, an autosampler, and a binary pump. The LC separation was
performed on an Agilent SB-Aq column (4.6 × 50mm, 5μm) with mobile phase A
(0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetontrile).
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The ﬂow rate was 0.3 mL min−1. The linear gradient was as follows: 0–1 min, 90%
A; 8–13min, 0%A; 13.5–18min, 90%A. The autosampler was set at 10 °C. The
injection volume was 10 μL. Mass spectra were acquired under positive electrospray
ionization (ESI) with the ion spray voltage of 5500 V. The source temperature was
450 °C. The curtain gas, ion source gas 1, and ion source gas 2 were 32 psi, 50 psi,
and 65 psi, respectively. Multiple reaction monitoring (MRM) was used for
quantitation: AEA m/z 348.3 → m/z 203.2; NADA m/z 440.2 → m/z 287.1; 14′,15′epoNADA m/z 456.3 → m/z 137.1; 14′,15′-epoNA5HT m/z 479.3 → m/z 160.1;
NA5HT m/z 463.3 → m/z 287.2. Internal standard AEA-d4 was monitored at m/z
352.3 → m/z 287.2.
Cell culture. HEK cells stably transfected with human TRPV1 (HEK-hTRPV1)
were a gift from Prof. Bradshaw (University of Indiana, Bloomington), which were
originally constructed by Merck Research. Cells were grown in Eagle Minimum
Essential Media supplemented with L-glutamine (EMEM) (ATCC) and 10% fetal
bovine serum (FBS) supplemented with penicillin (100 U mL−1) and streptomycin
(0.1 mg mL−1) and were incubated at 37 °C with 5% CO2. Cells were sub-cultured at
80–90% conﬂuency by trypsinization in a 1:6-1:10 ratio. HTLA cells for PRESTOTANGO and BV2 microglia were grown according to our previously established
protocol32. HTLA and BV2 cells were maintained in Dulbecco’s modiﬁed Eagle’s
media (DMEM) with 10% FBS with penicillin (100 U mL−1) and streptomycin
(0.1 mg mL−1) at 37 °C with 5% CO2 and sub-cultured at 80–90% conﬂuency by
trypsinization. HTLA cells were further supplemented with 2 μg mL−1 of puromycin and 100 μg mL−1 of hygromycin B.
Isolation and short-term culture of mouse DRG neurons. Mice were killed by
cervical dislocation following CO2 asphyxia and spinal columns were removed and
placed in ice-cold HBSS. Laminectomies were performed and bilateral DRGs were
dissected out. After removal of connective tissues, DRGs were digested in 1 mL of
Ca2+/Mg2+-free HBSS containing 20 U of papain (Worthington, Lakewood, NJ),
0.35 mg of L-cysteine and 1 μL of saturated NaHCO3 and incubated at 37 °C for
10 min. The DRG suspension was centrifuged, the supernatant was removed, and
1 mL of Ca2+/Mg2+-free HBSS containing 4 mg of collagenase type II and 1.25 mg
of Dispase type II (Worthington) was added and incubated at 37 °C for 15 min.
After digestion, neurons were pelleted; suspended in neurobasal medium containing 1% L-glutamine, 2% B-27 supplement, 100 U mL−1 penicillin plus 100 μg
mL−1 streptomycin, and 50 ng mL−1 nerve growth factor. The cells were plated on
a 12-mm coverslip coated with poly-L-lysine (10 μg mL−1) and cultured under a
humidiﬁed atmosphere of 5% CO2/95% air at 37 °C for 24 h.
Metabolism of NADA and NA5HT by BV2 microglia. BV2 microglia were plated
on 6-well plates at 5 × 105 cells per well and grown to 80–90% conﬂuency. Cell
growth media was exchanged for 2 mL of serum-free DMEM and cells were then
stimulated with 100 ng mL−1 of LPS for 12 h; control cells were without LPS stimulation. Afterwards, 1 μM of t-AUCB with or without 1 μM of the CYP inhibitor
SKF 525A were added for 30 min. 10 μM of NADA or NA5HT were then added for
30 min with or without 10 μM or 30 μM AEA. Cells were scraped into media and
combined with 2 mL ice-cold methanol. Cells were lysed using three consecutive
30-s on/off cycles on a water-bath sonicator. Cell debris was pelleted via centrifugation and the supernatant was puriﬁed using 100-mg Bond Elut C-18 cartridges (Varian, Harbor City, CA). Elution fractions were dried under reduced
pressure, resuspended in 150 μL of 180-proof ethanol, and analyzed as stated above
for tissue extractions. To account for batch-to-batch variability, data in the presence of AEA were analyzed based on a percentage to controls without AEA.
TRPV1 binding/activation measurements. Binding of NADA, NA5HT, and
epoxy-eVDs to TRPV1 was determined using an intracellular Ca2+ ﬂuorescent
quantiﬁcation method. HEK-hTRPV1 cells were grown for 3 passages after
recovery from frozen stocks before plating on Corning CellBind black, clearbottom 96-well ﬂuorescence plates coated with poly-L-lysine. After 24 h, media was
removed, and cells were loaded with 3 μM Fura-2 AM dye (Molecular Probes) in
sterile-ﬁltered HEPES-Tyrode Buffer (HTB) (Alfa Aesar) supplemented with 0.01%
Plurionic F-127 (Molecular Probes) for 20 min at room temperature. Analytes were
prepared from DMSO stocks in 150 μL HTB on separate 96-well plates so that
<0.1% DMSO was introduced to the cells. Dye was removed and cells were washed
twice with HTB and 100 μL of HTB was added to the cells for the assay. To conﬁrm
binding to TRPV1, 0.5 μM of the TRPV1-speciﬁc antagonist AMG-9810 was added
to this 100 μL of HTB prior to stimulating with agonists. Cells were then incubated
at room temperature for 20 min to allow for the de-acetylation of the dye. Fluorescence readings were conducted on a SpectraMax Gemini EM (Molecular Devices,
San José, Ca) plate reader using the following settings: bottom-read; channel 1—
340 nm excitation, 510 nm emission; channel 2—380 nm excitation, 510 nm
emission; 2-s mix before experiment; read every 14 sec; 5-min experiment. The
assays were conducted at room temperature (25 °C). 100 μL of agonists were
transferred in triplicate via multi-channel pipette to initiate the assay and the
ﬂuorescence intensities of both channels were measured over 5 min. The intensity
from channel 1 (Ca2+-bound Fura-2) was divided by the intensity from channel 2
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(Ca2+-free Fura-2) to achieve the Fluorescence Ratio
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. The Fluorescence

Ratio was then plotted over time. Owing to variations in the activation, the AUC of
the Fluorescence Ratio from 84–252 s was used to determine activation. The
average AUC of DMSO from 84–252 s was considered baseline and subtracted
from each data point. The AUCs were plotted as a function of concentration and
ﬁtted to a dose-response curve (Eq. 5) using OriginPro. CAP was used as a fullagonist positive control, and the Bmax of the CAP was deﬁned as 100% activation.
Antagonism experiments for NA5HT, 14′,15′-epoNA5HT, and AMG-9810 were
determined by adding varying concentrations of antagonist in 100 μL of HTB 15
min prior to stimulating with 250 nM CAP.
Animals. Male and female C57BL/6J mice were ordered from Jackson Laboratories
and were used at the age of 7–8 weeks. Mice were housed in a humidity- and
temperature-controlled environment under a 12-h light/12-h dark cycle with free
access to water and food. The mice were randomly used and all experiments were
done blind to genotypes of animals. All experimental procedures and animal care
were performed in accordance with the guidelines of the National Institutes of
Health and were approved by the Institutional Animal Care and Use Committee at
Washington University School of Medicine.

Quantitation of EET-EAs and eVDs using LC-MS/MS. Samples were analyzed
with the 5500 QTRAP LC/MS/MS system (Sciex, Framingham, MA) in Metabolomics Lab of Roy J. Carver Biotechnology Center, University of Illinois at UrbanaChampaign. Software Analyst 1.6.2 was used for data acquisition and analysis. The
1200 series HPLC system (Agilent Technologies, Santa Clara, CA) includes a
degasser, an autosampler, and a binary pump. The LC separation was performed
on an Agilent Agilent Eclipse XDB-C18 (4.6 x 150mm, 5 μm) with mobile phase A
(0.1% formic acid in water) and mobile phase B (0.1% formic acid in MeCN). The
ﬂow rate was 0.4 mL min−1. The linear gradient was as follows: 0–2 min, 90%A; 8
min, 55%A; 13–25 min, 40%A; 30 min, 30%A; 35 min, 25%A; 36–44 min, 0%A;
45–50 min, 90%A. The autosampler was set at 10 °C. The injection volume was
10 μL. Mass spectra were acquired under positive electrospray ionization (ESI) with
the ion spray voltage of +5000 V. The source temperature was 450 °C. The curtain
gas, ion source gas 1, and ion source gas 2 were 32, 65, and 55, respectively.
Multiple reaction monitoring (MRM) was used for quantitation: 14,15-epoNA5HT
m/z 479.3 → m/z 160.0; 14,15-epoNADA m/z 456.3 → m/z 137.1; 5,6-EET-EA,
8,9-EET-EA, 11,12-EET-EA, and 14,15-EET-EA are all measured with m/z
264.2 → m/z 62.0. Internal standards Anadamide-d4 and 14,15-EET-EA-d8 were
monitored at m/z 352.3 → m/z 287.2 and m/z 372.2 → m/z 63.0, respectively.
Binding equations. The general one-site binding equation used was Eq. 1 below

Live-cell Ca2+ imaging. Cultured DRG neurons were loaded with 4 μM Fura-2 AM
(Life Technologies) in culture medium at 37 °C for at least 60 min before use. Cells
were washed three times and incubated in HBSS at room temperature for 30 min.
Fluorescence at 340 nm and 380 nm excitation wavelengths was recorded on an
inverted Nikon Ti-E microscope equipped with 340-, 360-, and 380-nm excitation
ﬁlter wheels with NIS-Elements imaging software (Nikon Instruments Inc.). Fura-2
ratios (F340/F380) reﬂect changes in [Ca2+]i upon stimulation. Values were obtained
from 50–100 cells in time-lapse images from each coverslip. Threshold of activation
was deﬁned as 3 SD above the average (∼20% above the baseline).
Whole-cell Patch-clamp recording. Whole-cell patch-clamp recordings were performed using an Axon 700B ampliﬁer (Molecular Devices, Sunnyvale, CA, USA) with
Clampex 10.4 software (Molecular Devices). at room temperature (22–24 °C) on the
stage of an inverted phase-contrast microscope equipped. Pipettes were pulled from
borosilicate glass (BF 150-86-10; Sutter Instrument, Novato, CA, USA) with a Sutter
P-1000 pipette puller, which had resistances of 2–4 megaohms when ﬁlled with
pipette solution containing 140 mM KCl, 1 mM EGTA, 1 mM MgCl2, 5 mM MgATP
and 10 mM HEPES with pH 7.3 and 320 mOsm L−1 osmolarity. Cells were continuously perfused with extracellular solution containing the following: 140 mM NaCl,
2 mM CaCl2, 1 mM MgCl2, 5 mM KCl, 10 mM glucose and 10 mM HEPES, pH
adjusted to 7.4 with NaOH and the osmolarity was adjusted to ≈340 mOsm L−1 with
sucrose. Data were analyzed and plotted using Clampﬁt 10 (Molecular Devices).
PRESTO-TANGO binding with CB1 and CB2. Binding of eVDs to CB1 and CB2
was performed in HTLA cells using the PRESTO-TANGO assay as previously
described32. HTLA cells, (a HEK293 cell line stably expressing a tTA-dependent
luciferase reporter and a β-arrestin2-TEV fusion gene) were a gift from Brian
Roth’s lab. Cells were seeded at 20,000 cells per 100 µL into a poly-L-lysine coated
96-well plate. After 24 h, cells were transfected with cnr1 or cnr2 plasmids (0.1 µg
per well) using Calfectin (0.4 µL) in a 4:1 reagent to plasmid ratio (ﬁnal volume
110 µL per well). Transfection media was replaced after 18 h with fresh serummedia and maintained for 48 h. On the day of the assay, serum-media was replaced
with 100 µL media containing 1% dialyzed FBS for 4 h. Cells were then incubated
with 1 μM of t-AUCB for 30 min and then compound dissolved with media
containing 1% dialyzed FBS and was added in a log dose manner (ﬁnal volume 200
µL per well) and incubated for 8 h. Media was then exchanged for 40 µL of 20×diluted Bright-Glo (Promega, Madison, WI) solution and incubated in the dark for
20 min and analyzed by luminescence readings. CP-55940 was used as a fullagonist positive control for both receptors, and its Bmax was deﬁned as 100%
activity. For antagonism experiments, analytes were co-administered at varying
concentrations with 50 nM CP-55940.
Quantitation of epoxy-eVDs using LC-MS/MS. Samples were analyzed with the
5500 QTRAP LC/MS/MS system (Sciex, Framingham, MA) in Metabolomics Lab of
Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign.
Software Analyst 1.6.2 was used for data acquisition and analysis. The 1200 series
HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an
autosampler, and a binary pump. The LC separation was performed on an Agilent
SB-Aq (4.6 x 50mm, 5 μm) with mobile phase A (0.1% formic acid in water) and
mobile phase B (0.1% formic acid in MeCN). The ﬂow rate was 0.3 mL min−1. The
linear gradient was as follows: 0–1 min, 90%A; 8–13 min, 0%A; 13.5–18 min, 90%A.
The autosampler was set at 10 °C. The injection volume was 10 μL. Mass spectra
were acquired under positive electrospray ionization (ESI) with the ion spray voltage
of +5000 V. The source temperature was 450 °C. The curtain gas, ion source gas 1,
and ion source gas 2 were 30, 65, and 55, respectively. Multiple reaction monitoring
(MRM) was used for quantitation: 14′,15′-epoNA5HT m/z 479.3 → m/z 160.0;
14′,15′-epoNADA m/z 456.3 → m/z 137.1. Internal standard Anadamide-d4 was
monitored at m/z 352.3 → m/z 287.2.
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Bmax ½S
ð1Þ
K þ ½S
where Bo is the baseline response, Bmax is the maximum response, K is the binding
parameter, and [S] is the substrate concentration. For kinetic experiments, B and K
represent velocity and Km, respectively; for Soret binding experiments, B and K
represent ΔA and KD, respectively. For metabolism and Soret experiments, Bo = 0;
for NADPH metabolism Bo is a nonzero value.
Inhibition experiments were described by either a competitive model (Eq. 2) or
noncompetitive model (Eq. 3)
B ¼ B0 þ

B ½S
B ¼  max 
K 1 þ ½I
K þ ½S

ð2Þ

i

B¼

Bmax ½S


ðK þ ½SÞ 1 þ ½I
K

ð3Þ

i

where Ki is the afﬁnity of the inhibitor and [I] is the concentration of the inhibitor.
A general two-site binding equation (Eq. 4) was used to describe the
metabolism of NADA and NA5HT
B¼

B1 ½S
K1

þ BK2 ½S
K
1

2
2
2

1 þ K½S þ K½SK
1

1

ð4Þ

2

where B1 and B2 are the maximum metabolism at the ﬁrst site and second site,
respectively, and K1 and K2 are the afﬁnities at the ﬁrst site and second site,
respectively.
In cellulo data were ﬁtted to a dose-response equation (Eq. 5)
B ¼ B0 þ

Bmax  Bo
1 þ 10½ðB50 ½LÞp

ð5Þ

where [L] is the concentration of the ligand, p is the Hill coefﬁcient, B50 is the halfmaximal response (EC50 for agonism and IC50 for antagonism experiments), Bo is
the baseline response (bottom asymptote), and Bmax is the maximum response (top
asymptote).
Statistical analysis. Statistical signiﬁcance was determined by either a two-tailed
t-test with equal variance or a one-way ANOVA followed by a Tukey’s post-hoc
analysis as indicated in each ﬁgure legend. P-values < 0.05 were considered statistically signiﬁcant.
Modeling and simulation of CYP2J2. Initial structural models of membranebound CYP2J2 bound to AEA and NADA or NA5HT were generated with
molecular docking performed with AutoDock Vina63 in a stepwise manner as
described below. A grid box of dimension 22 Å in x, y, and z and centered in the
active site of CYP2J2 was employed for docking. We ﬁrst docked NADA or
NA5HT to our previous membrane-bound models of CYP2J236. From this
docking step, conﬁgurations of AEA/NADA/NA5HT in which the main epoxidation site (carbons C14 and C15) were close to the heme moiety (with distance
<5 Å) and with a high docking score, resulting in over 100 initial structures of
each molecule in complex with CYP2J2. The resulting structures were then
employed as receptors for docking of a second molecule (AEA for NADA/
NA5HT in active site, or NADA/NA5HT for AEA in active site). This second
step allowed us to explore potential peripheral binding sites (i.e., outside the
central active site cavity of CYP2J2), which were hypothesized from the
experimental. From docking, two potential peripheral binding sites were identiﬁed. For each peripheral binding conﬁguration, the corresponding CYP2J2
complexes with two molecules were sorted by docking score, and the models
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with the highest score were employed as starting conﬁgurations for MD simulations. Each simulation system was minimized for 2000 steps, and equilibrated
for 1 ns with the Cα atoms of CYP2J2 and the heavy atoms of the ligands (AEA,
NADA, and NA5HT) harmonically restrained (with force constant k = 1 kcal
per mol per Å2). Following this preparation step, the 2-molecule systems were
simulated for 50 ns.
Simulation protocol. The simulations were performed using NAMD264. The
CHARMM27 force ﬁeld with cMAP48 corrections was used for CYP2J2. The
CHARMM3665,66 force ﬁeld was used for lipids. Force ﬁeld parameters for AEA,
NADA, and NA5HT were generated by analogy from the CHARMM General
Force Field67. The TIP3P model was used for water68. Simulations were performed
with the NPT ensemble with a time step of 2 fs. A constant pressure of 1 atm was
maintained using the Nosé-Hoover Langevin piston method69. Temperature was
maintained at 310 K using Langevin dynamics with a damping coefﬁcient γ of
0.5 ps-1 applied to all atoms. Nonbonded interactions were cutoff at 12 Å, with
smoothing applied at 10 Å. The particle mesh Ewald (PME) method70 was used for
long-range electrostatic calculations with a grid density of >1 Å−3.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data generated or analyzed during this study are included in this published article
(and its supplementary information ﬁles). Other material is available from the
corresponding author on reasonable request. Material availability statement: All plasmids
used in the study are available from Addgene or can be obtained from the corresponding
author on request. All other data or resources are available from the corresponding
author upon reasonable request. Source data are provided with this paper.
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